

FILED BY SEDAR

May 20, 2022

British Columbia Securities Commission (**Principal Regulator**)
Alberta Securities Commission
Saskatchewan Financial and Consumer Affairs Authority
The Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission, New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Government of Newfoundland and Labrador
Office of the Superintendent of Securities, Prince Edward Island

Dear Sirs/Mesdames:

**RE: Mydecine Innovations Group Inc. (the “Company”)
Prospectus Supplement dated May 20, 2022 (to the Final Short Form Base Shelf
Prospectus for the Province of Québec and the Amended and Restated Final Short
Form Base Shelf Prospectus for each of the provinces of Canada except Québec,
each dated January 28, 2022) (the “Supplement”)**

We refer to the Supplement of the Company relating to an offering of units.

We, as counsel to the Company, hereby consent to the use of, and reference to, our firm name on page (iii) of the Supplement, our firm name and opinion under the heading “Certain Canadian Federal Income Tax Considerations”, and our firm name under the heading “Legal Matters and Interests of Experts”.

We confirm that we have read the Supplement and that we have no reason to believe that there are any misrepresentations in the information contained therein that are derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with the preparation of such opinions.

Yours truly,

MILLER THOMSON LLP

(Signed) Miller Thomson LLP